The use of tacrolimus in the treatment of inflammatory bowel disease

Expert Opinion on Drug Safety

Volumn 6, Issue 5, 2007, Pages 479-485

  Chow, Dorothy K L ^a   Leong, Rupert W L ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Colitis; Crohn's; Fistula; FK 506; Inflammatory bowel disease; Tacrolimus; Therapy

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CARBAMAZEPINE; CIMETIDINE; CLARITHROMYCIN; CYCLOSPORIN; DILTIAZEM; ERYTHROMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ITRACONAZOLE; KETOCONAZOLE; MERCAPTOPURINE; METHOTREXATE; METYRAPONE; NEVIRAPINE; PHENYTOIN; PLACEBO; PREDNISONE; RIFABUTIN; RIFAMPICIN; RITONAVIR; STEROID; TACROLIMUS; TIPRANAVIR; TROLEANDOMYCIN; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VERAPAMIL;

ALOPECIA; ANUS FISTULA; BONE MARROW SUPPRESSION; CARDIOMYOPATHY; CLINICAL TRIAL; COLON RESECTION; CRANIAL NERVE PARALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; ENTERITIS; ESOPHAGITIS; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GRAND MAL SEIZURE; HEADACHE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPOMAGNESEMIA; ILEITIS; INSOMNIA; LEUKOENCEPHALOPATHY; LIVER DYSFUNCTION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MENTAL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PARESTHESIA; PATHOGENESIS; PNEUMONIA; PRIMARY SCLEROSING CHOLANGITIS; PYODERMA GANGRENOSUM; SEIZURE; STUPOR; SUPERINFECTION; TREMOR; TUBERCULOSIS; ULCERATIVE COLITIS; VAGINA DISEASE; ANIMAL; CHEMISTRY; METABOLISM;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; HUMANS; INFLAMMATORY BOWEL DISEASES; TACROLIMUS;

EID: 35348975650     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.5.479     Document Type: Editorial

References (59)

1. PLOSKER GL, FOSTER RH: Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs (2000) 59(2):323.
2. BOUSVAROS A, LEICHTNER AM, BOOK L et al.: Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506). Gastroenterology (1996) 111:237-243.
3. VAN THIEL DH, CARROLL P, BU-ELMAGD K et al.: Tacrolimus (FK506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am. J. Gastroenterol. (1995) 90:455-459.
4. KUINOSE M, IWAGAKI H, MORIMOTO Y et al.: Calcineruin antagonists inhibit IFN-γ production by downregulation of interleukin-18 in human mixed lymphocyte reactions. Acta Med. Okayama (2000) 54:201-209.
5. LUO C, BURGEON E, CAREW JA et al.: Recombinant NFAT1 (NFATp) is regulated by calcineruin in T cells and mediates transcription of several cytokine genes. Mol. Cell Biol. (1996) 16:3955-3966.
6. + T cells of asthmatic patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporine A. Int. Immunol. (1995) 7:449-457.
7. SAKUMA S, KATO Y, NISHIGAKI F et al.: FK506 potently inhibits T cell activation induced TNF-α and IL-1β production in vitro by human peripheral blood mononuclear cells. Br. J. Pharmacol. (2000) 130:1655-1663.
8. TOCCI MJ, MATKOVICH DA, COLLIER KA et al.: The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J. Immunol. (1989) 143:718-726.
9. TANIGAWA T, PAI R, ARAKAWA T et al.: TGF-β signaling pathway: its role in gastrointestinal pathophysiology and modulation of ulcer healing. J. Physiol. Pharmacol. (2005) 56:3-13.
10. SCHREIBER S, NIKOLAUS S, HAMPE J: Activation of NF-κB inflammatory bowel disease. Gut (1998) 42:477-484.
11. ROGLER G, BRAND K, VOGL D et al.: NF-κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology (1998) 115:357-369.
12. NEURATH MF, BECKER C, BARBULESCU K: Role of NF-κB in immune and inflammatory responses in the gut. Gut (1998) 43:856-860.
13. TAKIZAWA H, SHINTANI N, NATSUI M et al.: Activated immunocompetent cells in rat colitis mucosa induced by dextran sulfate sodium and not complete but partial suppression of colitis by FK506. Digestion (1995) 56:259-264.
14. HASHIMOTO Y, MATSUOKA N, KAWAKAMI A et al.: Novel immunosuppressive effect of FK506 by augmentation of T cell apoptosis. Clin. Exp. Immunol. (2001) 125:19-24.
15. MIGITA K, ORIGUCHI T, KAWABE Y et al.: FK506 markedly enhances apoptosis of antigen-simulated peripheral T cells by down-regulation of Bcl-xL. Transplantation (1999) 68:1018-1023.
16. HORTELANO S, LOPEZ-COLLAZO E, BOSCA L: Protective effect of cyclosporine A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. Br. J. Pharmacol. (1999) 126:1139-1146.
17. CRENESSE D, LAURENS M, HEURTEAUX C et al.: Rat liver ischemia-reperfusion-induced apoptosis and necrosis are decreased by FK506 pretreatment. Eur. J. Pharmacol. (2003) 473:177-184.
18. PETERS DH, FITTON A, PLOSKER GL et al.: Tacrolimus. A review of its pharmacology and therapeutic potential in hepatic and renal transplantation. Drugs (1993) 46:746-794.
19. BRYNSKOV J, FREUND J, NORBY RASMUSSEN S et al.: Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease. Scand. J. Gastroenterol. (1991) 26:689-695.
20. LICHTIGER S, PRESENT DH, KORNBLUTH A et al.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. (1994) 330:1841-1845.
21. FEAGAN BG, MCDONALD JWD, ROCHON J et al.: Low-dose cyclosporine for the treatment of Crohn's disease. N. Engl. J. Med. (1994) 330:1846-1851.
22. KOZAREK R, BEDARD C, PATTERSON D et al. Cyclosporin use in the pre-colectomy chronic ulcerative colitis patient in the Pacific northwest. Gastroenterology (1994) 106(Suppl.):A715 (Abstract).
23. BAERT F, HANAUER S. CYA in severe steroid-resistant UC: long-term results of therapy. Gastroenterology (1994) 106(Suppl.):A648 (Abstract).
24. SMITH MB, HANAUER SB: Pneumocystis carinii pneumonia during cyclosporine therapy for ulcerative colitis. N. Engl. J. Med. (1992) 327(7):497-498.
25. KAPTURCZAK MH, MEIER-KRIESCHE HU, KAPLAN B: Pharmacology of calcineurin antagonists. Transplant. Proc. (2004) 36:S25-S32.
26. FELLERMANN K, TANKO Z, HERRLINGER KR et al.: Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm. Bowel Dis. (2002) 8:317-324.
27. CHRISTIANS U, JACOBSEN W, BENET LZ et al.: Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin. Pharmacokinet. (2002) 41:813.
28. BUCHMAN AL, PAINE MF, WALLIN A et al.: A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content. Dig. Dis. Sci. (2005) 50:2312-2315.
29. BHALOO S, PRASAD GV: Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report. Transplant. Proc. (2003) 35:2449-2451.
30. HEBERT MF, LAM AY: Diltiazem increases tacrolimus concentrations. Ann. Pharmacother. (1999) 33:680-682.
31. KATARI SR, MAGNONE M, SHAPIRO R et al.: Clinical features of acute reversible tacrolimus (FK506) nephrotoxicity in kidney transplant recipients. Clin. Transplant. (1997) 11:237-242.
32. SANDBORN WJ: Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulising Crohn's disease. Am. J. Gastroenterol. (1997) 92:876-879.
33. IERARDI E, PRINCIPI M, FRANCAVILLA R et al.: Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol. Ther. (2001) 15:371-377.
34. LOWRY PW, WEAVER AL, TREMAINE WJ et al.: Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm. Bowel Dis. (1999) 5:239-245.
35. SANDBORN WJ, PRESENT DH, ISAACS KL et al.: Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology (2003) 125:380-388.
36. GONZALEZ-LAMA Y, ABREU L, VERA MI et al.: Long-term oral tacrolimus. therapy in refractory to infliximab fistulising Crohn's disease: a pilot study. Inflamm. Bowel Dis. (2005) 11:8-15.
37. NG SC, AREBI N, KAMM MA: Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm. Bowel Dis. (2007) 13:129-134.
38. COLOMBEL JF, LOFTUS EV Jr, TREMAINE WJ et al.: The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 126:19-31.
39. LJUNG T, KARLEN P, SCHMIDT D et al.: Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm county. Gut (2004) 53:849-853.
40. FELLERMANN K, LUDWIG D, STAHL M et al.: Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FKS06). Am. J. Gastroenterol. (1998) 93:1860-1866.
41. HOGENAUER C, WENZL HH, HINTERLEITNER TA et al.: Effect of oral tacrolimus (FK506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther. (2003) 18:415-423.
42. OGATA H, MATSUI T, NAKAMURA M et al.: A randomized, dose-finding study of oral tacrolimus (FKS06) therapy in refractory ulcerative colitis. Gut (2006) 55:1255-1262. Erratum in Gut (2006) 55:1684.
43. RUTGEERTS P, SANDBORN WJ, FEAGAN BG et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. (2005) 353:2462-2476.
44. BAUMGART DC, PINTOFFL JP, STURM A et al.: Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease - a long-term follow-up. Am. J. Gastroenterol. (2006) 101:1048-1056.
45. CAMPBELL S, TRAVIS S, JEWELL D: Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur. J. Gastroenterol. Hepatol. (2005) 17:79-84.
46. JARNEROT G, HERTERVIG E, FRIIS-LIBY I et al.: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology (2005) 128:1805-1811.
47. CASSON DH, ELTUMI M, TOMLIN S et al.: Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut (2000) 47:436-440.
48. KHURRUM BAIG M, MARQUEZ H, NOGUERAS JJ et al.: Topical tacrolimus (FK506) in the treatment of recalcitrant parastomal pyoderma gangrenosum associated with Crohn's disease: report of two cases. Colorectal Dis. (2004) 6:250-253.
49. KIMBLE RM, TICKLER AK, NICHOLLS VS et al.: Successful topical tacrolimus (FK506) therapy in a child with pyoderma gangrenosum. J. Pediatr. Gastroenterol. Nutr. (2002) 34:555-557.
50. PETERING H, KIEHL P, BREUER C et al.: Pyoderma gangrenosum: successful topical therapy with tacrolimus (FK506). Hautarzt (2001) 52:47-50.
51. HOMEY B, ASSMANN T, VOHR HW et al.: Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary immune responses. J. Immunol. (1998) 160:5331-5340.
52. BAUMGART DC, WIEDENMANN B, DIGNASS AU et al.: Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis. Inflamm. Bowel Dis. (2004) 10:421-424.
53. DE OCA J, VILAR L, CASTELLOTE J et al.: Immunodulation with tacrolumus (FK506): results of a prospective, open-label, non-controlled trial in patients with inflammatory bowel disease. Rev. Esp. Enferm. Dig. (2003) 95:459-470.
54. HAIT EJ, BOUSVAROS A, SCHUMAN M et al.: Pouch outcomes among children with ulcerative colitis treated with calcineurin inhibitors before ileal pouch anal anastomosis surgery. J. Pediatr. Surg. (2007) 42:31-34.
55. BAUMGART DC, WIEDENMANN B, DIGNASS AU et al.: Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol. Ther. (2003) 17:1273-1281.
56. STAATZ CE, TETT SE: Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet. (2004) 43:623-653.
57. BAUMGART DC, STURM A, WIEDENMANN B et al.: Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut (2005) 54:1822-1823.
58. FRENCH AE, SOLDIN SJ, SOLDIN OP et al.: Milk transfer and neonatal safety of tacrolimus. Ann. Pharmacother. (2003) 37:815-818.
59. BAERT F, NOMAN M, VERMEIRE S et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. (2003) 348:601-608.